CRISPR Therapeutics AG (FRA:1CG) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1CG CRISPR Therapeutics AG FRA:1CG
41 GF Score
Price €43.03
GF Value €3.08
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:1CG vs ORKA, TVTX, MANE: Short Percentage of Float Comparison

For the Biotechnology subindustry, CRISPR Therapeutics AG's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CRISPR Therapeutics AG Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Short Percentage of Float falls into.


FRA:1CG
41GF Score
CRISPR Therapeutics AG FRA:1CG
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CRISPR Therapeutics AG (FRA:1CG) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of €43.03 is trading 1296.9% above its estimated GF Value™ of €3.08. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for FRA:1CG:

  • Short Percentage of Float:
  • GF Value™: €3.08 vs. price of €43.03 (1296.9% above fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the FRA:1CG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
41GF Score

Get the complete analysis for FRA:1CG

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.03
Price
€3.08
GF Value